LifestyledAI, Dongguk University Startup Technology Institute & UMUST R&D Partner | To Advance Global AI Deep Tech and Healthcare Businesses

On August 28, 2024, Dongguk University Startup Technology Institute announced the signing of a joint MOU with LifestyledAI Co., Ltd. and UMUST R&D to advance global deep tech and healthcare initiatives through the application of LifestyledAI’s cutting-edge, proprietary AI technologies (patent-pending).

With this agreement, the parties plan to promote mutual cooperation with the goals of:

  • Collaborating on AI-based technology development and commercialization
  • Establishing strategies and providing technical support for exploring overseas markets
  • Joint research and development (international joint R&D, workshops, and seminars)
  • Exchanging research personnel
  • Creating an industry-academia cooperation ecosystem for mutual growth

LifestyledAI is an AI deep-tech startup that seeks to revolutionize customer lifestyles through its proprietary AI-based technologies, including AI Ultra-Real Fitting for highly realistic virtual fashion and beauty try-ons, and a precise, easy-to-use AI body measurement system. With a vision to become a global leader in the practical application of AI image technology, LifestyledAI is dedicated to enhancing user convenience in the fashion and beauty e-commerce industries through its innovative AI solutions. As a resident company in Dongguk University’s Startup Incubation Center, it receives extensive support in areas such as international market expansion, industry-academia collaboration, faculty consulting, technology transfer, and commercialization.

UMUST R&D Co., Ltd. is a renowned global healthcare startup focused on the development of global healthcare and AI technologies. Its core areas of expertise include the development of AI-based medical devices and healthcare solutions, leveraging cutting-edge technologies to drive innovation in the medical industry.

Jinwan Kim, CEO of LifestyledAI:

“This partnership will allow us to further refine our proprietary AI technologies and accelerate their global commercialization, helping to advance the AI deep-tech and healthcare industries on a global scale.”

Director Gwangho Yoo, Head of Dongguk University Startup Technology Institute, commented

“This agreement will facilitate a collaborative research and development framework in the AI and healthcare sectors by leveraging in-house technologies and matching human resources to strengthen industry-academia collaboration.”

Kangpa Lee, CEO of UMUST R&D, stated, “We are dedicated to advancing the AI image technologies developed by LifestyledAI and working together to implement these innovations in the development of cutting-edge AI medical devices, while also enhancing our global business capabilities.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”